- Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023
NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (NASDAQ:AZN) completed the additional equity investment of $140M in Cellectis, as previously announced by Cellectis on November 1 and 15, 2023 (the "Additional Investment").
As part of the Additional Investment, AstraZeneca subscribed today for 10,000,000 "class A" convertible preferred shares and 18,000,000 "class B" convertible preferred shares, in each case at a price of $5.00 per convertible preferred share, issued by the board of directors of Cellectis pursuant to the authorizations granted by the extraordinary general meeting of the shareholders of Cellectis held on December 22, 2023.
Prior to their conversion into ordinary shares, the "class A" convertible preferred shares have single voting rights and will not be eligible for double ...